BACKGROUND: The design of chemotherapy-induction regimens for acute myeloid leukaemia (AML) is directed towards the early elimination of bone marrow (BM) leukaemic blast cells (LBCs). Patients with AML after induction show LBC reduction in a hypoplastic BM and also demonstrate a varying number of residual BM plasma cells (PCs). AIM: To relate PC number to several blood and BM parameters as well as clinical features such as infection and survival. METHODS: On the 14th day after the start of chemotherapy (D+14) BM samples were examined for residual PCs in 60 adult (>or=15 years) patients undergoing AML-induction chemotherapy, and the proportion of PCs was related to blood and BM parameters including French-American-British (FAB) subtype, other inflammatory cells, antecedent infection, attainment of complete remission and 36-month survival. RESULTS: Median PC proportion of 11.3% (range 0.1-48.7%) in D+14 BM aspirates and 10.7% (0.6-41%) in trephine biopsies was observed. Their number showed a direct relationship with residual BM lymphocytes (r=0.368; p=0.025). Higher numbers of residual PCs also reflected the presence of infection before diagnosis and coincident with treatment (p=0.039). Although we could not demonstrate an association between PC numbers and 36-month survival, PC numbers were significantly higher in patients with residual leukaemia at D>14 (p=0.007). CONCLUSION: D+14 BM PC number reflects the effectiveness of induction chemotherapy and the presence of antecedent inflammation or infection.
BACKGROUND: The design of chemotherapy-induction regimens for acute myeloid leukaemia (AML) is directed towards the early elimination of bone marrow (BM) leukaemic blast cells (LBCs). Patients with AML after induction show LBC reduction in a hypoplastic BM and also demonstrate a varying number of residual BM plasma cells (PCs). AIM: To relate PC number to several blood and BM parameters as well as clinical features such as infection and survival. METHODS: On the 14th day after the start of chemotherapy (D+14) BM samples were examined for residual PCs in 60 adult (>or=15 years) patients undergoing AML-induction chemotherapy, and the proportion of PCs was related to blood and BM parameters including French-American-British (FAB) subtype, other inflammatory cells, antecedent infection, attainment of complete remission and 36-month survival. RESULTS: Median PC proportion of 11.3% (range 0.1-48.7%) in D+14 BM aspirates and 10.7% (0.6-41%) in trephine biopsies was observed. Their number showed a direct relationship with residual BM lymphocytes (r=0.368; p=0.025). Higher numbers of residual PCs also reflected the presence of infection before diagnosis and coincident with treatment (p=0.039). Although we could not demonstrate an association between PC numbers and 36-month survival, PC numbers were significantly higher in patients with residual leukaemia at D>14 (p=0.007). CONCLUSION: D+14 BM PC number reflects the effectiveness of induction chemotherapy and the presence of antecedent inflammation or infection.
Authors: C E van der Schoot; P Jansen; M Poorter; M R Wester; A E von dem Borne; L A Aarden; R H van Oers Journal: Blood Date: 1989-11-01 Impact factor: 22.113
Authors: Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco Journal: J Clin Oncol Date: 2003-12-15 Impact factor: 44.544
Authors: K Inoue; H Sugiyama; H Ogawa; T Yamagami; T Azuma; Y Oka; H Miwa; K Kita; A Hiraoka; T Masaoka Journal: Blood Date: 1994-10-15 Impact factor: 22.113
Authors: R Harris; S R Zuhrie; C B Freeman; G M Taylor; J E MacIver; C G Geary; I W Delamore; P J Hull; J A Tooth Journal: Br J Cancer Date: 1978-02 Impact factor: 7.640
Authors: R L Powles; J Russell; T A Lister; T Oliver; J M Whitehouse; J Malpas; B Chapuis; D Crowther; P Alexander Journal: Br J Cancer Date: 1977-03 Impact factor: 7.640
Authors: Yeonsook Moon; Woo Ri Jang; Hyeon Gyu Yi; In Seo Park; Chung Hyun Nahm; Jong Weon Choi; Jin Ju Kim; Seung Baik Han Journal: Infect Chemother Date: 2013-12-27